Our History

Home » Our History
hearing testing

Vivosonic Inc. is a leader in the development of innovative technologies to enhance auditory evoked response detection. The Integrity™ V500 System is the only auditory evoked potential system with convenient wireless capabilities. Portable and easy to use, Integrity™ provides superior response detection in a greater range of environments, clinical populations and patient states. Patented and proprietary technologies significantly reduce the need for sedation during ABR measurement and enable testing in electrically noisy environments such as the NICU and O.R.

Since 1999, Vivosonic’s R&D activities have produced technological advancements that make it possible to obtain an earlier diagnosis, and test more patients, in more places:

• VivoLink™ wireless capabilities for freedom of movement during testing.
• VivoAmp™, based on the patented award-winning Amplitrode®, a combination of electrode and pre-amplifier for maximum noise reduction.
• Proprietary noise-reducing algorithm (SOAP™-Kalman) techniques for advanced signal processing of evoked potentials.


July 22, 1999 – Vivosonic Incorporated


2000 - Development of first product: VivoScan™ with DPOAE function

Since its formation, Vivosonic has focused on creating technologies to solve common problems in audiology testing. In 2000, the company developed its first product, the VivoScan™ with DPOAE function, which later received approval from the United States Food and Drug Administration (FDA) and Health Canada for sale, beginning in December 2001.

2002 - VivoScan™ Vivo 200 DPS


2003 - Vivoscan updated

2003 Vivo 200 DPS Version 2.0 device is substantially equivalent to Vivo 200 DPS OAE Audiometer.

2005 - FDA approval of Integrity

Vivosonic introduced Integrity™ to the world markets at Medica 2005, the world’s largest annual medical trade fair in Düsseldorf, Germany, and Arab Health 2006 medical fair in Dubai, UAE. Integrity presented at the 2006 American Academy of Audiology convention in Minneapolis, MN, the world’s largest Audiology annual meeting.

“Integrity represents a huge technological leap forward in the Audiology industry,“ says Isaac Kurtz, M.H.Sc., P.Eng., Vivosonic’s Director of Engineering and Research. “It solves the two fundamental problems clinicians experience in ABR testing – environmental electro-magnetic interferences and patients’ muscular motion artifacts.”


Integrity launched with ABR modality.  ECochG, DPOAE and TEOAE added later.

2005 - Demo sales to Northeastern

December 2005 - Integrity XP released


2006 - Sales to Turkey


2007 - AAA – Frost and Sullivan 2006 Technology Innovation Award

2007 - Newborn Hearing Screening Development Started – Neuroscreen


2008 – FDA Approval of Neuroscreen (based on Integrity)


2010 – Collaboration with CCHMC begins

2010 - Brazil Sales

2010 – Aurix released


2011 – ASSR released


2012 – Integrity G1 released

2012 – Integrity 7.02 - Windows 7 version of Integrity Software

2012 – China

Vivosonic’s products have been officially introduced in China with an event that included a traditional Chinese lion dance, symbolizing prosperity. The launch comes after Vivosonic received several regulatory approvals by the State Food and Drug Administration of the People’s Republic of China.




2013 – VCS introduced


2014 - Vivocheck

reduced electromagnetic interference equipmentThe VivoCheck™ is a portable, quick and easy-to-use tool, which helps ensure the Integrity™ V500 System is performing optimally in a particular clinical environment. The VivoCheck™ checks the system, identifies the best environment for testing, and establishes baseline data.

2015 – January Integrity G2 released Integrity 8 – Windows 10 version Integrity


2016 – Aurix

Aurix™ Newborn Hearing Screening System demonstrates that technology can be advanced without being complicated. This automated ABR system detects with speed and accuracy the presence or absence of potential hearing loss in infants 34 weeks gestational age to 6 months. Clinical findings report its practical benefits over popular systems on the market.

newborn hearing screening


2017 – Integrity ABR Screening with Diagnostic Testing

The availability of both screening and diagnostic modalities on one platform greatly increases convenience for users, making it possible to move from screening to diagnostic ABR without losing time when a Refer/Incomplete result is generated during initial screening.

Read more: http://bit.ly/ABR-one-platform

Unsedated BERA


2019 – Corticals and ER2 for G2